Gut and Orbital Dysbiosis Associated with Graves’ Disease and Graves’ Orbitopathy: A Systematic Review
Journal of Clinical Medicine · 12.06.2026 · 15 (12) · 4586
DOI: 10.3390/jcm15124586 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.06.2026. Verfasst von Abdel Mohaimen Missaoui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology-Diabetology-Nutrition, Poitiers University Hospital, 86000 Poitiers, France. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Graves’ disease (GD) is a prevalent autoimmune thyroid disorder marked by thyrotoxicosis, goiter, and Graves’ orbitopathy (GO). Recent studies highlighted its association with dysbiosis. This systematic review aims to update the current literature and clarify the distinctive microbial signatures and dysbiosis associated with GD/GO.
Methods
A systematic search for relevant studies was conducted across multiple databases (2000–2023), employing appropriate keywords. Relevant data were extracted from 25 eligible studies.
Results
Microbiota analysis from 19 GD studies (713 patients, 546 controls) and eight GO studies (356 patients, 187 controls), primarily conducted in China (21/25), were examined. The gut microbiota richness and evenness were reduced in GD patients compared to controls in 62.5% of fecal samples. No consistent pattern in alpha diversity was observed in GO. Significant taxonomic divergence was observed between GD/GO and controls. At the phylum level, the Firmicutes to Bacteroidetes ratio was consistently decreased in GD patients (66.7%). Most GO patients also exhibited a similar disequilibrium in their gut and orbital adipose microflora. At the genus level, Prevotella (11 studies), genera within the Lactobacillaceae family (three studies), and Streptococcus (three studies) consistently showed an increase. Genera from the families Lachnospiraceae (nine studies), Ruminococcaceae (six studies), and Veillonellaceae (five studies), as well as the genus Bacteroides (three studies), were decreased.
Conclusions
GD/GO-associated dysbiosis is characterized by reduced microbial richness and evenness and alterations in gut phyla balance (↓ Firmicutes, ↑ Bacteroidetes, ↑ Proteobacteria). Specific genera—including Lactobacillus, Prevotella, Bacteroides, and members of the Lachnospiraceae family—may plausibly act as contributors to the onset or progression of GD/GO by influencing the Th17/Treg balance, although their exact roles remain uncertain and largely hypothetical.
Systematic review registration
PROSPERO identifier CRD42024512007.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology-Diabetology-Nutrition, Poitiers University Hospital, 86000 Poitiers, France.
- University of Poitiers, 86000 Poitiers, France.
- Department of Endocrinology-Diabetology-Nutrition, Angoulême Hospital Center, 16000 Angoulême, France.
- Department of Internal Medicine and Endocrinology, Monastir University Hospital, Monastir 5000, Tunisia.
ORCID-Profile: Abdel Mohaimen Missaoui, Oumeyma Trimeche, Ekram Hajji, Helena Mosbah
Zitieren
APA
Missaoui, A. M., Trimeche, O., Hajji, E., & Mosbah, H. (2026). Gut and Orbital Dysbiosis Associated with Graves’ Disease and Graves’ Orbitopathy: A Systematic Review. Journal of Clinical Medicine, 15(12), 4586. https://doi.org/10.3390/jcm15124586
Vancouver
Missaoui AM, Trimeche O, Hajji E, Mosbah H. Gut and Orbital Dysbiosis Associated with Graves’ Disease and Graves’ Orbitopathy: A Systematic Review. Journal of Clinical Medicine. 2026;15(12):4586. doi:10.3390/jcm15124586
BibTeX
@article{Missaoui2026,
author = {Missaoui, Abdel Mohaimen and Trimeche, Oumeyma and Hajji, Ekram and Mosbah, Helena},
title = {Gut and Orbital Dysbiosis Associated with Graves’ Disease and Graves’ Orbitopathy: A Systematic Review},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4586},
doi = {10.3390/jcm15124586}
}
EUVIMED